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ABSTRACT
The epidemic of Coronavirus disease 2019 (COVID-19) caused by novel coronavirus SARSCoV-2 (severe acute respiratory syndrome, coronavirus 2) infection has been considered by the
World Health Organization (WHO) as a public health emergency of global interest. The efforts
nowadays of different countries focus on the fast isolation and fast diagnosis of patients as well as
to find possible therapeutic agent or vaccine. Several sites, articles, reports, reviews, and web pages
discussing COVID-19 virus and possible treatments were investigated, the data were collected between November-2020 and May-2021. Approximately 170 articles and reports were opened and
read, but nearly 80 of them were used for this review. Several drugs showed hopeful potential results such as colchicine, dexamethasone, kaletra (Lopinavir/ritonavir), cefuroxime, favipiravir, and
inhaled furosemide, but until now there is no WHO approved antiviral drug against COVID-19,
although remdesivir is approved by Food and drug administration (FDA) as antiviral for COVID19, but WHO doesn’t recommend it’s use. The protocol followed by WHO until now is a symptomatic treatment, e.g., antipyretics, antitussive, adequate nutrition, and rehydration, antibiotics if
suffering from secondary infection, antithrombotic prophylaxis for hospitalized COVID-19 patients, and corticosteroids in exacerbation cases. Fortunately, there are several vaccines that
reached an advanced phase in research trials, and the world is hopeful for mass vaccination in early
to mid-2021. Currently, there is no WHO-approved treatment for COVID-19, but there are many
other promising drugs/agents under investigation. Supportive care and protocols were followed to
manage the current crisis situation. However, many vaccines are approved for the prevention of
COVID-19 available now such as Vaxzevria (Astrazeneca vaccine), tozinameran (Pfizer/BioNTech
vaccine), Moderna: mRNA-1273 vaccine and Janssen COVID-19 vaccine while others are still in
clinical trials.
Keywords: COVID-19, SARS, PubMed, treatment.
respiratory tract, with the virus attacking the
INTRODUCTION
host cell through attached ACE-2 (angiotenThe first case of the communicable dissin-converting enzyme -2) via special virus
ease, called coronavirus disease 2019
surface glycoproteins (spikes) [2]. The virus
(COVID-19), appeared in December 2019 in
is found in considerable numbers in alveolar
Wuhan, China, caused by SARS-CoV-2 (secells, so the lungs are the most vulnerable
vere acute respiratory syndrome, coronavirus
organs, so there are a few scientists suggest2). It then diffused enormously and becomes
ing that decreasing ACE-2 activity can be
an ongoing pandemic. Until 24 November
protective [3].
2020, over 58,700,000 cases and over1.3 milRespiratory failure might develop as the
lion deaths have been reported. COVID-19
alveolar disease progresses. Because of the
was announced as a public health emergency
considerable expression of ACE-2 in the
of international concern on 30 January, 2020,
glandular cells of the gastric, rectal, and duoand as a pandemic on 11 March, 2020 [1].
denal epithelium, the virus also affects gasSARS-CoV-2 is linked to the known
trointestinal (GI) organs. Acute myocardial
SARS-CoV and belongs to the betacoronainjury and cardiovascular chronic damage
virus genus, however, it possesses a zoologihave been observed [4].
cal origin. It can affect the upper and lower
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Those patients that require ICU (intensive care unit) or have a high incidence of
thrombosis, show a poor diagnosis. One of
the common reasons for death is kidney
complications; in about 30% of patients in
China and New York hospitals, patients suffered from kidney injury (although some of
them did not have previous kidney problems), and acute respiratory distress syndrome [5].
The virus spreads easily through the air
between physically close people, via small
droplets produced from patient’s breath,
sneezes, coughs, or talking, and can also be
also transmitted via contaminated surfaces.
Patients can infect others two days prior to
the onset of symptoms. Infection persists for
around for 7–12 days in moderate cases, and
up to 14 days in more severe cases. Reverse
transcription polymerase chain reaction (rRtPCR) from a nasopharyngeal swab is used in
diagnosis as a standard method, while a CT
scan chest image can be helpful in the diagnosis of individuals with suspicion of infection, however, it is not recommended for routine screening.
According to symptom profiles, COVID19 has variable and nonspecific symptoms,
but the most common are fever and cough
(dry or productive), with other less common
symptoms of fatigue, shortness of breath, and
muscle, back and joint pain. About 40% of
patients suffer from temporary loss of smell
and taste senses, while some patients suffer
from gastrointestinal symptoms such as diarrhoea, nausea, sore throat, loss of appetite,
headache, and vertigo. The incubation period
for COVID-19 is 4 to 5 days; although some
patients do not experience any symptoms,
they can still spread the disease [6].

In this review article, we will be concerned about COVID-19 drugs management
drug, and assessing them through evaluation
of their possible mechanisms, safety profile,
and availability with cost considerations by
searching PubMed, Google Scholar and grey
literature search, articles and reviews discussing COVID-19 virus possible treatment.
Possible therapeutic agents
Antibiotics
Azithromycin
Azithromycin (Figure 1) is a macrolide
antibiotic. It binds to the 50S subunit of the
bacterial ribosome and inhibits bacterial protein synthesis and quorum sensing, decreasing biofilms formation through suppressing
protein production. It effectively accumulates
in cells (especially phagocytes) and is transported to infection sites in high concentrations. It is used in chronic inflammation, such
as diffusive panbronchiolitis, posttransplant
bronchiolitis, and rosacea. It also used in respiratory, dermal, urogenital, and other bacterial infections. It has an immunomodulatory
property also, so it is used in cystic fibrosis,
COPD (Chronic obstructive pulmonary disease) exacerbations, and non-eosinophilic
asthma [8].

To minimize infection, transmission,
frequent hand washing, social distancing,
covering coughs, and keeping unwashed
hands away from the face and face mask are
recommended.

Azithromycin is usually well tolerated;
the most common side effects are GI discomfort, headache and dizziness, and transient
changes in transaminases in 1.5% of patients.
Hearing loss or damage has also been reported, especially in patients with COPD, and in
some patients, it appears to be irreversible;
there were about 20 case reports that have
been published about hearing loss associated
with short-term use of azithromycin. QT prolongation and torsades de pointes, which can
result in death may occur; an alert was given
by the FDA to recognise the possibility of a
fatal heart rhythm due to azithromycin [9].
Azithromycin does not significantly interfere
with CYP 450 3A4.

Until now, there is no specific proven
treatment for COVID-19, but there are several ongoing studies. Management involves
treating symptoms, isolation, and supportive
care with antivirals, antibiotics, corticosteroids, supplements, alone or in combination
[7].

Azithromycin shows good activity
against influenza virus and zica virus, but it
does not work against COVID-19, so they
have tried to mix it with hydroxychloroquine
in trials. This resulted in 95% of patients recovered after 8 days, but they do not know
why this occurs with this medication. How-
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ever, the latest (HFHS) trial in Southeast
Michigan involved patients admitted to the
health system from 10 March, 2020 to 12
May, 2020 with COVID-19. The study was
carried out on 2541 patients 18 years of age
or older. They were divided into groups according to the treatment they had received:
hydroxychloroquine alone, combination therapy of hydroxychloroquine and azithromycin, and the azithromycin alone group. They
concluded that combination therapies of hydroxychloroquine and azithromycin were
linked to COVID-19 mortality reduction.

An online survey discovered that
azithromycin was the second most prescribed
medication for COVID-19, and it confirmed
that the president of the USA took azithromycin combined with other medicines [10].
Doxycycline
Doxycycline (Figure 1) is a tetra-cycle
derivative antibiotic, which binds to the 30S
subunit of bacterial ribosomes and inhibits
bacterial protein synthesis. Protein synthesis
is also inhibited by binding to the 70S subunits of mitochondrial ribosomes. It is a bacteriostatic agent.

Figure (1): Chemical structures of some drugs’ candidates for COVID19.
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It enters into the inner cytoplasmic
membrane through the bacterial cell membrane and is a pH-dependent active transport
system. It inhibits inflammatory-cellgenerated proteolytic enzymes. It has a good
activity against a wide variety of Gram +ve,
Gram –ve, and atypical bacteria. It also has
activity in certain protozoa such as malaria.
Doxycycline is used for respiratory tract infections, sexually transmitted infections and
prophylaxis from malaria and some arthropod-borne rickettsia infections. According to
the safety profile, doxycycline has major GI
and dermatologic side effects. It is contraindicated in pregnancy and in children due to
discolouration of developing teeth and it has
effects on bone. It interacts with antacids,
iron, oral contraceptives, and methotrexate.
Long term use of these antibiotics affects the
growth of the male reproductive tract, but it
has not been fully clarified [11].
In a prospective study done on 100
COVID-19 patients to evaluate the combination therapy between Ivermectin and
Doxycycline as a potential therapy for
COVID-19. The results show that patients
between 4 and 18 days of the beginning of
treatment were negative for corona virus and
their clinical condition improved. In a mild to
moderate cases of COVID-19, the combination between doxycycline and ivermectin is
very effective in viral clearance [12]. Multicenter study is needed to evaluate this therapy to be included in the global guideline.
Cefuroxime
Cefuroxime (Figure 1) is a secondgeneration cephalosporin. It is a cell wall
inhibitor and interferes with its synthesis,
inhibiting peptidoglycan cross-linking. Cefuroxime is a bactericidal drug. It also plays a
role in the activation of autolysis of bacterial
cell wall.
Common side effects associated with
this drug are maculopapular rash, pruritis,
urticaria, anaphylaxis, eosinophilia, thrombocytopenia, neutropenia, leucopenia, diarrhoea
and interstitial nephritis [13].
It is used for soft tissue infections, respiratory tract infections and genitourinary
tract infections. Use in CNS (Central nervous

system) is under investigation. It has an excellent penetration into bone and joints, but
clinical data are insufficient to recommend its
use in these infections [14].
Cefuroxime is a potential inhibitor for
three important proteins in SARS-CoV-2
(protease, RNA dependent polymerase, and
ACE2 Spike complex) cefuroxime is ranked
as a top potential protein inhibitor drug for
COVID-19 [15]. There are many ongoing
studies on cefuroxime.
Antivirals
Favipiravir
Favipiravir (Figure 1) is a prodrug of a
purine nucleotide, which inhibits an important enzyme in replication and transcription of the viral genome RNA polymerase. It
is used routinely for influenza, Ebola, and
Lassa virus treatment, and in trials for
COVID-19 treatment.
The Japanese Ministry of Health approved favipiravir as a resistant influenza
drug, with no clear adverse effects in 2014.
However, it has many side effects, for example, weight loss, vomiting, reduced the production of red blood cells, increased liver
function, increased vacuolisation in hepatocytes, and it is teratogenic [16].
Few clinical experiences have shown
positive results about using favipiravir for
COVID-19. One of the clinical experiences
was a random, prospective study for 120 patients with moderate to severe COVID-19
taking favipiravir compared with 120 patients
who took arbidol, resulting in an observed
difference in clinical recovery at day 7 of
treatment within moderate infection (55.9%
arbidol and 71.4% favipiravir, P = 0.019),
however, there was no noticeable differences
within severe or moderate to severe cases.
The second one was a study of 80 patients participating in clinical tests in China,
including 35 patients who took favipiravir
and 45 patients who did not. It showed that
favipiravir treatment shortened the time of
curing compared with control group patients.
However, another multicentred randomised
clinical study at Wuhan University hinted
that favipiravir treatment was not better.
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Nevertheless, medical treatment teams have
recommended treatment with favipiravir and
included it within COVID-19 diagnosis and
treatment plan [17].
Tamiflu (Oseltamivir)
Oseltamivir (Figure 1) is approved for
the treatment of influenza A and B, and similarly, zanamivir (Relenza®) is also FDA approved only for influenza A and B treatment.
Both drugs are similar in structure and are
comparably potent in inhibiting neuraminidase enzymes (which stimulate the viruses’
release from infected cells and enhances the
respiratory tract’s viral movement and effects
the replication of the virus). The neuraminidase enzyme, expressed on the viral surface,
is inhibited by oseltamivir. Virion remains
bound to the membrane of infected cells in
the presence of a neuraminidase inhibitors
and are also ensnared in respiratory secretion
[18].
Oseltamivir is suitable for adult and paediatric patients that have acute, uncomplicated influenza A or B, including neonates 14
days, and older, neonates younger can also
receive the drug, but the safety and efficacy
have not been identified in this population.
There is some evidence in hospitalised patients that oseltamivir may be effective up to
4 to 5 days after the onset of symptoms, and
therefore, guidelines support ordering the
drug in patients with serious or progressive
influenza or in high-risk patients with complicated illness, irrespective of the onset of
symptoms [19].
Vomiting, diarrhoea, dizziness, headache, nose bleeding, redness of the eyes or
pain, problems with sleep or coughing or
other breathing issues, and extreme mental
mood changes can rarely be triggered by
Tamiflu, this may be more likely in infants
[20].
Research in Wuhan reported that after
receiving oseltamivir antiviral treatment in
COVID-19 patients, there were no positive
results were observed. The efficacy of the
drug in SARS-CoV-2 infection is still were
tested in further trials. Oseltamivir is also
used with other drugs such as chloroquine
and favipiravir in clinical trials [21].

Another Study looked at 13 COVID-19
suspected medical groups and their cohabitation families’ hypoxia-free who had arrived
in a clinic from March to May, 2020. Antibacterial and antiviral therapy (mainly oseltamivir) was given jointly to all patients, and
the results showed that oseltamivir administration partially decreased temperature
within 24 hours. Clinical data was compared
between patients that received it in the early
treatment period (within 24 hours), and others who received it in the late treatment period (after 24 hours); the result showed that the
fever period in the early treatment group was
shorter than the late treatment group. Our
findings indicate that the early administration
of oseltamivir in combination with antibacterials can decrease the temperature in free hypoxia COVID-19 patients [22].
Ritonavir/Lopinavir (kaletra)
Lopinavir
is
a
novel protease inhibitor (PI) formed from ritonav
ir (Figure 1). Co-administration with lowdose ritonavir greatly increases the pharmacokinetic properties and, thus, the anti-HIV-1
protease activity of lopinavir. Co-formulated
lopinavir/ritonavir has been developed as a
part of combination therapy with other antiretroviral agents for ease of administration
and to ensure that both medicines are taken
together [23].
It is used in HIV disease by inhibiting
the HIV protease enzyme via the formation
of an inhibiter enzyme complex, so that some
immature, non-infectious viruses will be produced. It also seems that it is the mechanism
in fighting SARS-CoV-19 is the same in
SARS-CoV and MERS-CoV.
The 3-Chymotrypsin like protease
(3CLpro) enzyme plays a big role in viral
RNA processing, since lopinavir is a protease
inhibitor. Thus, the activity of 3-CLpro can
be inhibited, affecting the process of viral
replication and released from the host cell. In
patients undergoing lopinavir/ritonavir-based
regimens, diarrhoea, nausea, and asthenia are
commonly recorded adverse effects, with
increased total cholesterol, triglyceride and
hepatic enzyme levels also recorded [24].
Recent evidence indicates that lopinavir
has in vitro anti-SARS-CoV-2 antiviral activ-
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ity, although there is no C2-symmetric pocket in the coronavirus proteases, like 3-CLpro
[25].
In a study following 127 COVID-19 patients in Hong Kong, 86 patients in the combination group received ritonavir, lopinavir,
ribavirin, and interferon-b, while the others in
the control group received lopinavir and ritonavir only. The results showed that the
combination group had a shorter time of viral
shedding and hospital stay than the control
group. Another significant trial finding was
that patients on lopinavir/ritonavir had a
shorter time of 6 days in the ICU compared
to 11 days in others. This is useful, however,
as in the current pandemic there is a shortage
of ICU beds. In conclusion, there is a significant shorter hospital stay for patients taking
lopinavir/ritonavir in combination or alone
[26].
Umifenovir
Umifenovir (Figure 1; also called arbidol) is an indole carboxylic acid derivative,
which is considered a broad-spectrum antiviral which acts by inhibiting viral fusion with
the host’s cell membrane, so that it prevents
viral entry. It is licensed to be used in influenza A a and B treatment and prophylaxis in
China and Russia. It also shows a good activity against SARS-CoV hepatitis B [27]. Later
on, it demonstrated its antiviral activity in
Ebola, human herpes virus 8, and hepatitis C
viruses [28].
The use of Umifenovir in COVID-19
remains unclear. A retrospective study was
done on 81 non-intensive care unit covid-19
confirmed patients, with 45 patients receiving
oral umifenovir (0.2 g three times a day), and
others were not. After 1 week, the same
negative rate of COVID-19 in pharyngeal
swab was shown, thus, in other words,
umifenovir treatment did not alter the duration of infection and hospital stay in non-ICU
patients [29]. However, other systematic reviews and meta‐analyses studies with 1052
patients found that umifenovir on day 7 was
not associated with higher negative rates (rate
of positive to negative conversion), but on
day 14 it was associated with higher negative
rates [30].

Studies have shown that arbidol and lopinavir\ritonavir combination therapy was associated with noticeable elevated negative
conversion rates, and chest CT scans showed
improvements
compared
with
lopinavir\ritonavir monotherapy [31].
All clinical studies available on
umifenovir have several limitations in study
design and sample size. It seems that
umifenovir monotherapy is not effective, but
combinations of umifenovir with other antivirals might be beneficial in viral clearance
and chest CT. improvement.
Remdesivir
Remdesivir (Figure 1) is an analogue of
adenosine nucleotide. It is a prodrug broadspectrum antiviral against RNA viruses, inhibiting important viral enzymes called RNA
polymerase, and it has activity against several coronaviruses such as MERS virus (Middle East Respiratory Syndrome) [32, 33]. It
also has good antiviral activity against Ebola
virus [34, 35].
Remdesivir is one of the most COVID19 promising drugs, and there are many case
reports and clinical trials that have shown its
effectiveness. Remdesivir was used in the
first COVID-19 infected case treatment in the
US. Firstly, he had received parenteral vancomycin and cefepime, but on day 7 of hospitalisation (day 11 of illness), he developed
severe pneumonia, and so physicians decided
to start antiviral therapy (remdesivir) and
discontinued the previous drugs. Treatment
with IV remdesivir was started on day 7. On
day 8, the patient’s clinical condition was
improved [36].
A cohort study was done on 53 patients
receiving remdesivir (64% of them needed
invasive ventilation). After follow-up from
taking the first dose of remdesivir, 68% of
patients showed an improvement in the clinical condition, whereas 15% showed a worsened condition. Seven of the 53 patients died
after the completion of remdesivir treatment
[37].
A randomised, placebo-controlled, double-blind study was done on 236 patients
(158 taking remdesivir and 79 taking placebo) within 10 days of symptom onset. The
results showed that remdesivir was not asso-
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ciated with noticeable clinical improvement
or reduction in mortality, although it numerically reduced the time needed for clinical
improvement (the median was about 21 days
with remdesivir, versus 23 days with placebo) [38].
Another double-blind, randomised, placebo-controlled trial of IV remdesivir was
done on 1059 patients (538 taking remdesivir
and 521 taking placebo). The results showed
a significant shortened recovery time in those
who took remdesivir (the median of recovery
time was 11 days with remdesivir versus 15
days with placebo), and it also showed a noticeable reduction in the mortality rate (7.1%
with remdesivir, and 11.9% with placebo)
[39]. The researchers stated that larger studies were needed to confirm the results.
Remdesivir is given by IV administration because it has a poor oral absorption and
is taken by 200 mg IV loading dose on day 1,
then 100 mg daily maintenance dose for 5 to
9 days [40]. Some studies recommend combining nebuliser inhalation of remdesivir and
IV administration to increase the distribution
of remdesivir to the lungs [41].
Remdesivir has a low affinity for human
enzymes (human RNA polymerase II and
human mitochondrial RNA polymerase), so it
has an acceptable safety profile in humans.
The most common adverse effects are increased hepatic enzymes, increased blood
glucose, anaemia, and renal impairment [39].
On October 15, WHO solidarity trial
published, its results of a RCT study that involve more than seven thousands COVID-19
patients that Remdesivir has no significant
impact on mortality rate reduction, clinical
improvement or the need for mechanical ventilation[42]. However, on October 22, FDA
approved Remdesivir use in COVID-19 and
became the first drug approved by the US
FDA. [43], however on 20th of November,
WHO recommends against the use of it in
COVID-19 patients regardless of disease severity, as there is no evidence to improve
survival.[42]
Hydroxychloroquine
Hydroxychloroquine (Figure 1) is a 4aminoquinoline. It has anti-malarial, antiautophagy, anti-inflammatory, and immuno-

suppressive activity, but the exact mode of
action is unknown. It may inhibit the immune
function through changing the presentation of
antigens and the production of cytokines.
Hydroxychloroquine raises the pH of lysosomes, which impairs the degradation of autophagic proteins, hydroxychloroquinemediated ineffective autophagosomes, accumulation might end in the death of cells that
relay on autophagy to survive.
Additionally, this drug is extremely active against erythrocytic strains such as malaria, P. vivax, and different strains of P. falciparum, but it is not effective against the
gametocytes of P. falciparum. It accumulates
within the malarial parasitic lysosomes and
raises the pH of the vacuole, which affects its
ability to proteolyse hemoglobin to inhibit
the growth and development of the parasite.
It may also affect the action of parasitic heme
polymerase leading to the accumulation of
toxic beta hematin. Hydroxychloroquine accumulates in human organelles and increases
their pH, which interferes with the processing
of antigens and prevents the dimerisation of
the alpha and beta MHC II chains [44].
The most common use of hydroxychloroquine is as an anti-rheumatologic agent in
systemic lupus erythematosus (SLE) and
rheumatoid arthritis (RA), because it acts as
an immunosuppressant that inhibits the
rheumatoid factor and acute phase proteins
assembly. Additionally, hydroxychloroquine
accumulates in WBC, stabilises the lysosomal membrane, and inhibits collagenase and
protease enzymes.
The most common side effects of hydroxychloroquine are nausea, diarrhoea, rash,
skin pigment and hair alterations, and muscle
weakness. Therapy with hydroxychloroquine
is not associated with liver function abnormalities, but it may be a very rare reason for
acute liver injury. Hydroxychloroquine in
rare cases can cause anaemia and visual
changes or loss of vision, so it is recommended to do an eye examination within the
first year of use, and then repeat it every one
to five years as per current guidelines. Reports of heart rhythm abnormalities are also
reported, particularly along with other medications [45].
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On 28 March, 2020, the FDA permitted
the distribution and utilisation of hydroxychloroquine for hospitalized COVID19 patients, because the initial in vitro studies
showed that hydroxychloroquine may have
utility in fighting coronavirus, because it has
antiviral activity due to endosomal pH elevation that inhibits viral particles fusion, and
entry into host cells. In addition, it also inhibits the terminal glycosylation of ACE-2 (the
receptor that SARS-CoV and SARS-CoV-2
use to enter target cells), and it also has antiinflammatory and anti-thrombotic activity
[46].
On 21 March, 2020, president trump
claimed that hydroxychloroquine can prevent
and treat COVID-19. After one week from
this declaration, prescriptions of hydroxychloroquine were increased up to 200%
compared to previous years. The majority of
excess prescriptions were written between 14
March and 4 April, because news spread
about deficiency and shortage of this drug
without any evidence to support its use. Research now shows that hydroxychloroquine is
not effective in the prevention or treatment of
COVID-19, but the damage has already occurred, and thousands of USA citizens have
unnecessarily taken this medication, which
may have serious side effects. In addition,
people who really need hydroxychloroquine
found themselves unable to get the drugs that
they needed [47].
On 17 June, 2020, the WHO declared
that hydroxychloroquine utilisation in the
treatment of COVID-19 was being stopped
because the available data showed that hydroxychloroquine does not reduce the mortality rate reduction among COVID-19 patients.
[48]
Dexamethasone
Dexamethasone (Figure 1) is one of the
most common long-acting glucocorticoids,
just like a natural hormone produced by the
adrenal gland (36–55 h). It stimulates hepatic
glucose production by enhancing gluconeogenesis, and as a result, it raises glucose
plasma levels and body energy, so increasing
body resistance to stress. It also decreases
eosinophils, basophils, monocytes, and lymphocytes, but increases haemoglobin, erythrocytes, and platelets, but the most important

therapeutic properties of glucocorticoid are
its anti-inflammatory and immunosuppressive actions by blocking the power of macrophages and inhibiting the energy of leukocytes to retort to antigens and mitogens, and
reduce the production of cytokines. In addition, it can block the phospholipase A2 enzyme, which blocks arachidonic acid liberation, leading to anti-inflammatory and suppression expression of inflammatory mediators. At high levels, it provides negative
feedback to reduce ACTH production, so
suppressing the synthesis of glucocorticoids
and thyroid-stimulating hormone. It is thirty
times more potent than cortisol [49].
Dexamethasone has many uses: it is employed as a test for Cushing’s syndrome, relieves inflammation in different organs in our
body, decreases fluid accumulation of water
(oedema), is related to cancer in the brain or
spine, decreases inflammation in the eye, can
prevent or treat hypersensitivity reactions, is
a treatment of kinds of autoimmune diseases,
e.g., rheumatoid arthritis; conditions in the
skin, lung conditions (asthmatic patients),
and is used as a therapy for spreading tumours such as lymphoma, multiple myeloma
and leukaemia. In addition, it can be used for
patients who are having chemotherapy to
reduce and treat side effects including nausea
and vomiting. In cancer patients, we can use
it as an appetite stimulant, especially for patients with very severe appetite problems,
and it can be used in cases of adrenal insufficiency as a replacement therapy, to accelerate
foetal lung maturation, and immunosuppressant in transplantation procedures [50].
There are various adverse effects of
long-term therapy. In osteoporosis, it can
repress the absorption of Ca+2 intestinally
and reduce the formation of bone. It can interfere with hormone production (e.g., sex
hormones), create aa Cushing like syndrome
(distribution of fat become’s different with a
moon face, hair growth and increased need of
food), cataracts and glaucoma can also occur,
plus hyperglycemia, so that DM patients
should monitor their blood glucose level. In
addition, long-term use can decrease WBC
and increase the risk for infection, cause
hypokalemia, emotional disturbances (euphoria, depression), peripheral oedema, increase
the risk of hypertension and increase appe-
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tite. Topical therapy can cause atrophy in the
skin, purple stria, and bruising [51].
This drug must be tapered slowly, because sudden discontinuation can cause serious results if the patient has the suppression
of HPA axis, so it can cause acute adrenal
insufficiency which can be fatal. Coronavirus
stimulates inflammation as a normal response
of the body to defend against the the virus,
but in some cases, the immune system goes
into overdrive because the immune system
attacks own cells. Dexamethasone lowers and
calms this effect, so it is only used for those
that are receiving oxygen or on mechanical
ventilation. Hospitalized patients with
COVID-19 in the United Kingdom have been
tested in the national clinical trial RECOVERY (Randomized Evaluation of COVID-19
therapy) trial, which was established as a
randomized clinical trial to test a possible
therapy for COVID-19 patients. Among them
was dexamethasone, given to about 11,500
patients in hospitals in the UK; 2104 patients
received 6 mg dexamethasone per day (by IV
injection or by mouth) for ten days and were
compared with 4321 patients who took ordinary care alone. The 28-day death rate was
elevated in people who needed oxygen
(41%), among patients who received usual
care alone, intermediate in patients who
needed oxygen (25%), and the percentage
among people who did not require any respiratory intervention was the lowest (13%).
Dexamethasone treatment showed a reduction in mortality in about one-third of
people with COVID-19 on ventilators, and
about one-fifth of patients who needed oxygen only. In other words, it saved one life in
every eight patients on ventilators, and one
life in every twenty-five patients on oxygen.
It was administered as oral (liquid or tablet) or by intravenous route. It can be taken as
6 mg once daily for ten days, but they gave
prednisolone (a milder corticosteroid) for
pregnancy or breastfeeding women. A Professor of Emerging Infectious Diseases said,
“Dexamethasone is the first drug to be shown
to improve survival in COVID-19, so dexamethasone should now become the standard
of care in these patients. Dexamethasone is
inexpensive and easily available.”

On 22 July, 2020, the Ministry of Health
of Japan approved the employment of the
dexamethasone glucocorticoid drug as a novel treatment of coronavirus patients [52].
Ivermectin
Ivermectin (Figure 1) was discovered in
the 1970s as an anthelmintic agent. It stimulates GABA gate and Cl channels resulting in
organism paralysis, and it is an immunomodulator of host response, to activated neutrophils, C- reactive protein, and IL-6 (interleukin-6) [53]; then it was used as an antiviral
against certain flavivirus, e.g., dengue fever,
Japanese encephalitis, tick-borne encephalitis
virus, and chikungunya virus [54].
Ivermectin is marketed in doses of 200
mcg/kg for strongyloidesstercoralis (an intestinal parasite capable of causing severe systemic disease), and for onchocerciasis, or
liver blindness, and against lymphatic filariasis, and scabies as single doses of up to 400
mcg/kg, 200–300 mcg/kg doses within a
month are recommended for the treatment of
severe crusted scabies. Although it is not
marketed for these indications, ivermectin
has partial efficacy against other common
intestinal parasites in humans such as Ascarislumbricoide and Trichuristrichura. It is
also used out of labels against ectoparasites
like head lice, and Tungapenetrans among
many other internal or external parasites [55].
At currently approved doses, ivermectin
is very safe, because most adverse reactions
are mild and associated with parasite death
rather than with the drug itself, e.g., nausea,
skin rash, dizziness, suppressing immunity,
abdominal cramps, fever, heart rate elevation
and unstable BP. Ivermectin targets are only
present in invertebrates. Mammals only having a similar channel that could cross-react
with ivermectin (GABA-gated chlorine
channel), but it is only expressed in the central nervous system, which is protected by the
blood-brain barrier. There is no evidence that
indicates its employment in children or pregnancy. It is safely administered at 600
mcg/kg daily for three days [56].
In April 2020, studies on ivermectin
demonstrated that ivermectin in combination
with the antibiotic doxycycline, and zinc
supplement is effective in COVID-19 treat-
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ment. However, at the current time, we still
do not have definitive clinical trials to
demonstrate this. Regarding observational
studies and physician thought, there were 16
current clinical trials about ivermectin. These
studies are unlikely to be beneficial due to
the small sample size, poor study design, and
combining ivermectin with other drugs.
In vitro studies on monkey cells show
that ivermectin can block SARS-CoV-2 replication within 2 to 3 days of exposure to
ivermectin, through preventing the movement of viral proteins in and out of the nucleus of the host cells, which is crucial for
viral replication [57]. The problem is with the
potential overdose of ivermectin (more than
the recommended dose is required), which
can increase the potential of side effects and
it may cross the blood-brain barrier, causing
visual impairment, hamper the CNS (that
may affect heart rate, respiration and consciousness) [58].
Finally, the results of clinical trials are
needed to decide if ivermectin is effective
against COVID-19 or not. In Peru and Bolivia, the Ministries of Health have authorised
this drug for this indication.
Anticoagulants
COVID-19 can be associated with several haematological disorders that can lead to
coagulopathy. Several patients with COVID19 have existent coagulopathy similar to other systemic coagulopathies in critical infections, such as disseminated intravascular coagulation (DIC) or thrombotic microangiopathy. The percentage of thrombotic disorders
in patients with COVID-19 infection who
enter in ICU is 31%, which is clearly high
[59].
To clarify how coagulopathy occurs in
COVID-19, there are many mechanisms that
could be involved. One of these theories is
about the endothelial cells that play a serious
role in hemostasis regulation, fibrinolysis,
and the integrity of the vessel wall. An injury
to the endothelial cell will activate multiple
proinflammatory cytokines such as IL-1, IL6, and TNF-alpha (Tumour Necrosis Factor
alpha). The rise in the activity of inflammation can contribute to microvascular thrombosis [60].

The most common finding in patients
with COVID-19 and coagulopathy is an elevation in D-dimer levels, but decreased platelet count (present in 70–95% of patients with
intense COVID-19), and prolongation of prothrombin time. Mean fibrinogen levels are
higher than normal borders. However, an
abrupt decline in the blood level of fibrinogen was detected shortly before death in
many patients. Plasma levels of antithrombin are higher in COVID-19 survivors
than in nonsurvivors (91% of normal survivors vs 84% in nonsurvivors) [61].
A retrospective study was done including 183 patients with novel coronavirus
pneumonia (NCP) reported that the overall
mortality was 11.5%. There were 71.4% of
nonsurvivors and 0.6% survivors who met
the criteria of DIC during their hospital stay,
this can lead us to conclude that the abnormal
coagulation is linked with bad prognosis because it is common in deaths with NCP [62].
This has led to the introduction of anticoagulant therapy. 449 Patients with COVID19 were introduced to a study where they
gave heparin to 99 patients (mainly LMW
heparin) for 7 days at least. There was no
variation in mortality between patients who
took heparin and who did not take heparin
within 28-day (30.3% vs 29.7%). However,
the 28-day death rate among patients who
took heparin was less than in patients who
did not take it in patients with sepsis‐induced
coagulopathy (SIC) score ≥4 (40.0% vs
64.2%), or D-dimer >6 times of the upper
border of normal (32.8% vs 52.4%). Anticoagulant treatment seems to be linked to better
prognosis in severe COVID19 patients [63].
Any hospitalised patients who do not
have any proof of active bleeding should receive anticoagulants as a prophylactic measure, as COVID-19 infection is associated
with thrombosis. The anticoagulation of
choice is LMWH (such as enoxaparin 0.5
mg/kg), unfractionated heparin, or subcutaneous fondaprinux. If pharmacological anticoagulants are contraindicated, mechanical
thromboprophylaxis like intermittent pneumatic devices (IPD) should be used [60].
COVID-19 related morbidity and mortality may contribute to thrombotic events,
and the use of anticoagulants is linked to a
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better prognosis. However, the individualised
risk-benefit ratio of the use of anticoagulants
must be determined.
Colchicine
Colchicine (Figure 1) is a molecule
composed of tricyclic alkaloids extracted
from a plant known as Colchicum autumnale
(autumn crocus), which is commonly used to
treat various types of diseases and some syndromes like familial Mediterranean fever
(FMF; known as auto inflammatory disease
caused by mutations in the Mediterranean
fever gene, the characteristics of this disease
are fever, abdominal lining inflammation,
pain in lung line joint, swelling and ankle
rash). Colcicine is also used to prevent gout
attacks (a disease caused by the accumulation
of uric acid in blood, where uric acid makes
very hard crystals in joints cause that cause
sudden and very severe pain in joints in
adults) [64].
It also used for Behcets disease (an uncommon syndrome that causes blood vessel
inflammation throughout the body), coronary
artery disease, pericarditis (inflammation and
soreness of the pericardium, the fibrous sac
surrounding the cardiac muscle), and other
inflammatory and fibrotic conditions.
The pharmacotherapeutic mechanism of
action for this drug is from its ability to relate
to the molecular biology known as tubulin. It
can prevent the polymerization of the polymers of tubulin that form part of the cytoskeleton microtubules, which are important
to maintain the shape of the cell [65, 66].
Colchicine can block cell division during
metaphase when it binds to tubulin, and form
colchicine complexes with the protein forming a complex bounding to the ends of microtubules to stop the prolongation of the microtubule polymer, affecting the immune system
[67].
Its main technique is the suppression of
chemotaxis of neutrophils and the release of
a glycopeptide crystal-derived chemotactic
factor (CCF) from neutrophil lysosomes after
phagocytosis. Monosodium urate crystals
(MSU) cause stimulation of a chemotactic
factor called S100A8-9, which is believed to
be a similar factor to CCF and is supposed to
amplify neutrophil recruitment.

Elevated levels of proinflammatory neutrophilia and cytokines are one of the signs
that can be detected in COVID-19 patients
with severe acute respiratory syndrome. In
this situation, there is no medication, but
supportive, additional therapy and nursing
care try to decrease the inflammation. Colchicine works on leukocytes, and so is utilised as a support therapy.
One double-blind, controlled trial on
colchicine used in COVID-19 treatment
(which had a positive outcome) was done on
38 moderate to severe COVID-19 patients
from 11 April to 6 July, 2020, with the first
group taking 0.5 mg colchicine twice daily,
the second group not. The first endpoints for
this trial were the need for supplemental oxygen, time of hospitalisation, requirement for
the intense nursing unit, and mortality rate; as
secondary endpoints, they measured serum
C-reactive protein, serum lactate dehydrogenase, and the relationship of lymphocytes
to neutrophils in peripheral blood samples
from zero day to day 7.
The results showed that the median time
needed for additional supplemental oxygen
was 3.0 (1.5 to 6.5) days for the first group,
versus 7.0 (3.0 to 8.5) days for the second
group (the percentage of patients needing
oxygen supplement on day 2 was 53% versus
83%, but on day 7 the values were 39% versus 61% in the control, and colchicine
groups, respectively), and the first group
showed a noticeable reduction in C-reactive
protein levels. The use of colchicine did not
affect the cardiac muscle, however, the main
adverse effect with its use was diarrhoea
[67].
In summary, colchicine was found to decrease hospitalisation and oxygen supplement
need, and thus, it is considered a beneficial
and not expensive option for COVID-19
treatment.
Inhaled Furosemide
Inhaled Furosemide (Figure 1) is classified as a loop diuretic, which is a weak organic acid, with a relatively short half-life
and low volume distribution, leading to a low
distribution. However, the drug’s clearance
mostly happens in the kidneys (85%), and
around half of the drug is metabolised to glu-
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curonic acid, with the rest secreted unchanged in the urine.
To achieve its diuretic effect, furosemide
can be given orally, intravenously, or inhaled. The mechanism of the drug is to block
the reabsorption of sodium, potassium, and
chloride in both the proximal distal tubules
and in the loop of Henle. It takes effect after
60 to 90 minutes and promotes the excretion
of potassium, chloride, and sodium in the
urine [68].

Even though cytokine storms are known
to have a considerable role in very intense
viral pneumonia, the detailed mechanism of
hypercytokinemia in COVID-19 is not yet
fully delineated.
Inhalation of furosemide has been used
in the past for a variety of pulmonary disturbance and concerns as a safe way. Therefore, we suggest an evaluation of inhaled
nebulised furosemide in COVID-19 patients
because of its inflammatory effect [68]

Furosemide has antiinnate immune system activity; this effect was noticed when
they used the inhaled form of furosemide, but
not orally, and caused exercise-induced bronchospasm in asthmatic patients. Since then, it
has been approved as a possible treatment for
patients suffering from shortness of breathing
and symptomatic dyspnea. It mainly depends
on supposing that the volume of affected
edematous cells in the airway will be decreased by the diuretic effect of the drug, resulting in an improvement in the respiratory
tract. However, some current studies show
that its therapeutic effect comes from the decreased secretion of proinflammatory cytokines, particularly its effect on IL-6 and IL-8
and TNF-alpha.

After this, although the drug is found
globally and it has anti-inflammatory, antiviral effects, it is still unapproved.

This drug has an anti-inflammatory effect, has a good effect against dyspnea, and
shows antiviral effects. It blocks the
K+/Na+/Cl co-transporter in viruses, which
increases the concentration of Na+ and K+,
and as a result, increases the cell volume of
the virus leading to membrane distribution
and death.

Convalescent (or immune) plasma refers
to plasma that is collected from people after
recovery from infection and their development of antibodies. Passive administration of
these antibodies during convalescent plasma
transfusion offers a short-term method to
supply immediate immunity for an infected
person. Convalescent plasma from recovered
people is more promising when it is administered as a prophylaxis or when it is given
shortly after the appearance of symptoms
(within two weeks) [70].

Hypokalemia, i.e., electrolyte depletion,
is a possible disadvantage of using furosemide in COVID-19 patients. Inhalation
using a nebuliser mask will cause the evolution of aerosols and may elevate viral prevalence if done without physical distancing.
Because coughing is a primary way for disease spreading, and since inhaled furosemide
reduces coughing, it can reduce the spread of
the disease.
Furosemide helps in the early and late
stages of COVID-19, by blocking pulmonary
failure progress in the early stages, and reducing ventilator support needed in later
stages.

Interleukin-6 inhibitors (Tocilizumab)
Tocilizumab is a recombinant humanized monoclonal antibody that can inhibits
the binding of IL-6 to both soluble and membrane IL-6 receptors. Early evaluations from
China founded some improved outcomes in
hospitalised COVID-19 patients with who
received tocilizumab. These early reports
were followed by a few observational works
in critically ill COVID-19 patients with, that
suggested a mortality benefit with this drug
[69].
Convalescent plasma (CP)

Convalescent plasma is obtained by using apheresis (continuous blood centrifugation to permit a selective collection of plasma). During apheresis, they obtain neutralising antibodies (Nabs), clotting factors, antiinflammatory cytokines, defensins, natural
antibodies, and other proteins. The major
goal is to neutralise pathogens to allow its
eradication. [71].
Passive immunisation has been successfully used in the treatment of infectious diseases in previous years. It was used in Span-
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ish influenza (it is the first viral infection
where convalescent plasma was found to be
effective during clinical studies) [72], Ebola
virus [73] and influenza A (H1N1) [74] . Additionally, Convalescent plasma was used in
other coronavirus’ such as SARS-CoV [75],
MERS outbreaks [75].
The donor is a person who has recovered
from COVID-19. Recovery is defined as a
normal body temperature for at least three
days, no respiratory symptoms, and negative
results for COVID-19 for two consecutive
PCR tests at least three weeks after the appearance of symptoms. The donor has for be
negative to anti-HBV, HCV, HIV and positive for anti SARS-CoV-2 [76].
Convalescent plasma is a good agent to
be tested as a potential therapy to face this
pandemic. Several studies (but unfortunately
not clinical trials) have evaluated this option.
From 23 Januaryto 19 February, 2020, ten
patients in three hospitals participated in a
pilot study. All of them were diagnosed to
have severe COVID-19 and were admitted to
the ICU to receive antiviral therapy; some of
them were receiving antibiotics, antifungals,
corticosteroids, and oxygen when necessary.
A single dose of 200 ml of inactivated CP
was administered over four hours to ten patients, and researchers studied the safety and
clinical improvement after convalescent
plasma transfusion. The result was that all
symptoms in all patients disappeared or
largely improved after one to three days upon
convalescent plasma transfusion [77].
Another study of a case series of five
critically ill patients who had COVID-19 and
ARDS with severe pneumonia and continuously elevated viral load, despite taking antiviral treatment. All patients received convalescent plasma and within three days of transfusion, the body temperature of four of five
patients became normal, viral load decreased
and became negative within 12 days after
transfusion; ARDS improved in 4 patients
after 12 days. The limitation of this study
was the small sample size and concomitant
treatment with other drugs (such as
remdesivir, corticosteroids, etc.), however, it
suggested that convalescent plasma transfusion is safe, and decreased viral load and improved the clinical condition [78]. The dose
of convalescent plasma was 3.125 ml/kg (for

a typical adult patient of 80 kg they need 250
ml of plasma for three days) [70].
According to the safety profile of CP
transfusion, a study done on 5000 hospitalized patients with life-threatening COVID-19
found the incidence of all dangerous adverse
reactions (such as severe allergic reactions,
lung injury, circulatory overload) in the first
4 hours was less than 1%, and the mortality
rate was not excessive [79]. These indicate
that CP is safe for hospitalized COVID-19
patients.
Human plasma obtained from recovered
patients of COVID-19 is a safe and possibly
effective treatment for SARS-CoV-2. However, it is important to perform randomized
clinical trials to assure its efficacy.
Herbal and food supplements
Artemisia annua
Artemisia annua belongs to the Asteraceae family and is used as an anti-malarial,
due to its active compound, artemisinin [80].
It also contains many essential oils which
have anti-inflammatory [81], antitumor [82],
antibacterial and antioxidant properties [83].
Semi-synthetic derivatives of artemisinin, such as di-hydro artemisinin, βartemether, and artesunate have been developed with more potency, stability, and water
solubility, because artemisinin has poor water
solubility and bioavailability [84].
Currently, studies show that it has antiviral activity against SARA-CoV-2, by inhibiting chymotrypsin-like protease (CLPro) (an
enzyme produced by the virus during infection). It also supports adaptive immunity and
modulates the inflammatory response by regulating proinflammatory cytokines such as
PG-E2, IL-6, IL-10, and TNF-alpha, and may
also be used in fever treatment [85].
Artemisia annua is a possible candidate
to use in COVID-19, but more studies are
required to prove its safety and efficacy.
Vitamin D
Vitamin D is a fat-soluble supplement
with substantial benefits for the immune system. It regulates the production of a protein
that selectively kills infectious agents, enhances pathogen-fighting by white blood
cells (WBC), and decreases inflammation.
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There are many people with low concentrations of vitamin D, which affects the immune
function negatively, so increasing the risk of
respiratory infections including COVID-19,
and worsening the COVID-19 patient status.
We advise all older adults, hospital inpatients, nursing home residents, and other vulnerable groups to take vitamin D supplement
with 20–50 µg/d to enhance their resistance
to COVID-19 [86].
Vitamin C
The key factor of fatality in COVID-19
disease is acute respiratory distress syndrome
(ARDS), because of a significant increase in
free radicals and cytokines leading to cellular
injury, organ failure and death; therefore, the
early using of big dose vitamin C as an antioxidant may be efficient in these patients.
The latest clinical trials reaching high
doses of vitamin C were found to protect
against viral infection. It has a tolerated safety profile in high doses of oral administration, and even intravenously, so it should be
included in COVID-19 treatment and protection.
Vitamin C and other antioxidants are
currently using to alleviate COVID-19 associated with ARDS, because of the development of effective vaccines and long-term
treatment.
There is a significant need for clinical
studies to develop protocols for bedside use
[87].

Zinc
Zinc has antiviral activity by viral replication suppression and by immune response
support. It is considered an inexpensive and
effective adjunct therapy for some viral species that can trigger respiratory tract infection.
It is available as a tablet, lozenges, etc.,
alone or in combination with other supplements, for example, vitamin C. Maintaining
sufficient zinc blood levels is important to
protect from microorganisms, including
COVID-19, so consuming about 50 mg of
zinc per day will provide an additional shield
against COVID-19.
To prove the beneficial role of zinc in
COVID-19 disease, more clinical validations
are required [88].
1.

Combination Therapy that Eliminates
COVID-19 Virus

Among the choices for accelerating and
progressing the treatment of COVID-19, a
combination therapy was the best. This strategy is attractive for a number of reasons.
Firstly, combining two or more drugs with
related or complementary therapeutic effects
provides a multipronged effect, addressing
the mutable pathways of the virus. Secondly,
the combination may give a synergistic effect, and as a result may be better outcomes.
Thirdly, this plan is time-saving, rather than
taking a step-by--by-step treatment approach
(monotherapy), and this strategy begins with
testing all relevant therapeutic options (Table
1).

Table )1(: Drug combination list and the classification of each drug use.
Drug combination
Hydroxychloroquine and azithromycin
Lopinavir, ritonavir and ribavirin
Ivermectin and Doxycycline
Remdesivir with baricitinib, or with leronlimab
Triple combination antiviral therapy (lopinavir, ritonavir, and ribavirin) with interferon
beta-1b
Inhalable Gapme and anti-viral drug

Classification of drugs
Drug Name
Approved use
Hydroxychloroquine
Antimalarial
Azithromycin
Antibiotics
Lopinavir, ritonavir and Antiviral
ribavirin
Ivermectin
Anthelmintic
Doxycycline
Antibiotics
Remdesivir with baricitinib, Antiviral
or with leronlimab
lopinavir, ritonavir, and Antiviral
ribavirin
Gapme

Antiviral
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Drug combination
Nitazoxanide and azithromycin
Ivermectin and Doxycycline with Zinc and
Vitamin D3
Colchicine and Hydroxychloroquine
and Ivermectin
Colchicine with chloroquine or hydroxychloroquine and azithromycin
Ivermectin and Nitazoxanide
Colchicine along with Ivermectin
2.

WHO approved the clinical management protocol?

Patients with mild COVID-19 were recommended only to receive symptomatic
treatment such as antipyretics, e.g.: paracetamol (at present there is no evidence for adverse effects in patients who were taken nonsteroidal anti-inflammatory drugs (NSAIDs)
for fever) and anti tussive for cough, they
should receive adequate nutrition and appropriate rehydration.
WHO does not recommend antibiotics
therapy or prophylaxis for patients with mild
COVID-19 disease unless they suffer from
secondary infection.
Signs, symptoms, and complications
should be provided to the patient’s caregiver,
in case he seeks urgent care. Thrombosis
prophylaxis, such as low molecular weight
heparin is recommended in hospitalized patients with COVID-19 by WHO.
WHO does not recommend routine systemic corticosteroids using, unless they indicated for other reasons including exacerbation cases, ARDS, and who needs oxygen or
ventilator [89].
3.

Vaccines

World Health Organization (WHO) estimated that there are more than hundred current vaccines are under development, some
of these vaccines reach human trial phase
[90]. Some examples on these vaccines: First

Classification of drugs
Drug Name
Approved use
Nitazoxanide
antiprotozoal
azithromycin
antibiotics
Ivermectin
Anthelmintic
Doxycycline
antibiotics
Zinc and Vitamin D3
dietary supplement
Colchicine
anti-gout
Hydroxychloroquine
Antimalarial
Ivermectin
Anthelmintic
Colchicine
anti-gout
chloroquine
Antimalarial
azithromycin
antibiotics
Ivermectin
Anthelmintic
Nitazoxanide
antiprotozoal
Colchicine
anti-gout
Ivermectin
Anthelmintic
of them is Pfizer/BioNTech vaccine, it’s
RNA vaccine, it’s given by IM injection in
two doses on day 0 and 21 [91]. Data from
large studies showed that it’s 95% effective
in COVID-19 prevention, recommended for
older than 12 years old [92]. This vaccine
faces distribution challenges because it
should be stored at -94 degree Celsius [93].
Other vaccine is AstraZeneca/Oxford it’s a
Non-Replicating viral vector (it consist of
engineered virus that carry COVID 19 genes,
it can’t replicates because it does not have
DNA), it’s given by IM injection in two doses on day 0 and after 4 to 12 weeks, it recommended for older than 18 years old [91].
Phase III interm analysis indicates that its
76% effective in preventing COVID-19 [94].
It can have kept in refregirator (not freezing)
so it is easier to distributed, but there have
been cases reported venous clots, so in England it was recommended other vaccines for
people older than 40 years old. Moderna
vaccine its RNA vaccine (mRNA to generates viral spike proteins), it recommended for
older than 18 years old , it’s given by IM injection in two doses on day 0 and 28, [91]. It
should kept at -20 degree Celsius which
makes a challenge to transport it [95].
Moderna announced that their vaccine is 94%
effective [96]. Regarding the last updated
data of COVID-19 vaccines, forty vaccines
are under clinical evaluation, the national regulatory authorities have granted emergency use authorizations for some COVID19 vaccines, a few of them such as Oxford–
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AstraZeneca, Pfizer-BioNTech, SinopharmBBIBP, Moderna, and Sinovac, have been
approved for emergency use by at least
one WHO-recognized stringent
regulatory
authority [97, 98].
Researchers found a study in Spain that
show a mixing thereby with both the AstraZeneca and Pfizer, COVID-19 vaccines this
combination make an effective immune response against the virus SARS-CoV-2. Experience of more than 600 people results from
the advertise on 18 May in an online presentation are the first to presentation the benefits of mixing various coronavirus vaccines.
A United Kingdom (UK) trial of an identical
strategy reported safety data last week, and is
predictable to deliver further findings on immune responses soon. A study in Britain
called Com-COV, which mixed the same
type of two vaccines, found that people in the
mix-and-match groups had common vaccinerelated side effects, such as fever, compared
to people who received the two doses. From
the same vaccine 1. In Spain's CombivacS
trial, mild side effects were common, and
similar to those of standard COVID-19 vaccine regimens. None of it was considered
severe [99, 100].
CONCLUSION
The COVID-19 pandemic represents the
greatest global public health crisis in the last
ten decades, potentially since the influenza
outbreak of 1918. Scientists worldwide are
working hard to find an effective therapy,
learning from previous outbreaks of SARS
and MERS. There are several ongoing clinical trials on preexisting drugs to evaluate
their efficacy and safety, many of these drugs
have hopeful potential results such as colchicine,
dexamethasone,
kaletra
(Lopinavir/ritonavir), cefuroxime, favipiravir and
inhaled furosemide. However, until now
there is no available approved drug to use in
COVID-19 by WHO, although the FDA approved Remdesivir using in COVID-19 and
became the first drug approved by the
US.FDA, WHO recommends against the use
of remdesivir in COVID-19. A supportive
care and many protocols (symptomatic
treatment, e.g., antipyretics, antitussive, adequate nutrition, rehydration, antibiotics suffer
from secondary infection, antithrombotic

prophylaxis for hospitalized COVID-19 patients and corticosteroids in exacerbation
cases) were followed by governments and
organizations. Many vaccines passed phase 3
in research trials, and the scientists hope that
it will be ready for mass distribution in early
to mid - 2021.
Declarations
Ethics approval and consent to participate
Not applicable
Consent for publication
Not applicable
ACKNOWLEDGMENTS
The authors would like to thank AnNajah National University for their support.
Availability of data and materials
The datasets used and/or analyzed during
the current study are available from the corresponding author on reasonable request.
Competing interests
The authors declare that they have no
competing interests.
FOUNDING
Not applicable.
REFERENCES
1) WHO. WHO Coronavirus Disease
(COVID-19) Dashboard. 24/11/2020 at
19:47 2020.
https://covid19.who.int/?gclid=CjwKCA
iA-_L9BRBQEiwA-bm5fnuQm0EYt0UXTwp80lnYqXrkEOkYN6bbWybo1NJC6wPOXt0AsR1B
oCKS8QAvD_BwE (accessed
24/11/2020 at 19: 47 2020).
2) Mostafa-Hedeab G. ACE2 as Drug
Target of COVID-19 Virus Treatment,
Simplified Updated Review. Reports of
Biochemistry & Molecular Biology.
2020; 9(1): 97.
3) Rothan HA, Byrareddy SN. The
epidemiology and pathogenesis of
coronavirus
disease
(COVID-19)
outbreak. Journal of autoimmunity.
2020: 102433.

Palestinian Medical and Pharmaceutical Journal (PMPJ). 2022; 7(2): 117-138 ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ

Abdel Naser Zaid, et al.  ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ133

4) Zhang H, Li H-B, Lyu J-R, Lei X-M, Li
W, Wu G, et al. Specific ACE2
expression in small intestinal enterocytes
may cause gastrointestinal symptoms
and injury after 2019-nCoV infection.
International Journal of Infectious
Diseases. 2020; 96: 19-24.
5) Xu L, Liu J, Lu M, Yang D, Zheng X.
Liver injury during highly pathogenic
human coronavirus infections. Liver
International. 2020; 40(5): 998-1004.
6) Lauer SA, Grantz KH, Bi Q, Jones FK,
Zheng Q, Meredith HR, et al. The
incubation period of coronavirus disease
2019 (COVID-19) from publicly
reported confirmed cases: estimation and
application. Annals of internal medicine.
2020; 172(9): 577-582.
7) Hu H, Ma F, Wei X, Fang Y.
Coronavirus fulminant myocarditis
treated with glucocorticoid and human
immunoglobulin.
European
heart
journal. 2020.
8) Parnham MJ, Haber VE, GiamarellosBourboulis EJ, Perletti G, Verleden GM,
Vos R. Azithromycin: mechanisms of
action and their relevance for clinical
applications.
Pharmacology
&
therapeutics. 2014; 143(2): 225-245.
9) McMullan
BJ,
Mostaghim
M.
Prescribing azithromycin. Australian
prescriber. 2015; 38(3): 87.
10) Arshad S, Kilgore P, Chaudhry ZS,
Jacobsen G, Wang DD, Huitsing K, et al.
Treatment with hydroxychloroquine,
azithromycin, and combination in
patients hospitalized with COVID-19.
International journal of infectious
diseases. 2020; 97: 396-403.
11) Holmes NE, Charles PG. Safety and
efficacy review of doxycycline. Clinical
Medicine Therapeutics. 2009;1:CMT.
S2035.
12) Alam MT, Murshed R, Bhiuyan E, Saber
S, Alam RF, Robin RC. A case series of
100 COVID-19 positive patients treated
with combination of ivermectin and
doxycycline. Journal of Bangladesh
College of Physicians and Surgeons.
2020: 10-15.

13) Dhumal RS, Rajmane ST, Dhumal ST,
Pawar AP. Design and evaluation of
bilayer floating tablets of cefuroxime
axetil for bimodal release. 2006.
14) Harrison
CJ,
Bratcher
D.
Cephalosporins: a review. Pediatrics in
review. 2008; 29(8): 264.
15) Durojaiye AB, Clarke J-RD, Stamatiades
GA, Wang C. Repurposing cefuroxime
for treatment of COVID-19: a scoping
review of in silico studies. Journal of
Biomolecular Structure and Dynamics.
2020: 1-8.
16) Furuta Y, Gowen BB, Takahashi K,
Shiraki K, Smee DF, Barnard DL.
Favipiravir (T-705), a novel viral RNA
polymerase inhibitor. Antiviral research.
2013; 100(2): 446-454.
17) Chen C, Huang J, Cheng Z, Wu J, Chen
S, Zhang Y, et al. Favipiravir versus
arbidol for COVID-19: a randomized
clinical trial. MedRxiv. 2020.
18) Andraos J. Global green chemistry
metrics
analysis
algorithm
and
spreadsheets: evaluation of the material
efficiency performances of synthesis
plans
for
oseltamivir
phosphate
(Tamiflu) as a test case. Organic Process
Research & Development. 2009; 13(2):
161-185.
19) Dharan NJ, Gubareva LV, Meyer JJ,
Okomo-Adhiambo M, McClinton RC,
Marshall SA, et al. Infections with
oseltamivir-resistant influenza A (H1N1)
virus in the United States. Jama. 2009;
301(10): 1034-1041.
20) Fuyuno I. Tamiflu side effects come
under scrutiny. Nature Publishing
Group; 2007.
21) Wu R, Wang L, Kuo H-CD, Shannar A,
Peter R, Chou PJ, et al. An update on
current therapeutic drugs treating
COVID-19. Current Pharmacology
Reports. 2020:1.
22) Chiba S. Effect of early oseltamivir on
COVID-19-suspected
outpatients
without hypoxia. 2020.

 ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــPalestinian Medical and Pharmaceutical Journal (PMPJ). 2022; 7(2): 117-138

134 “ ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــA review of possible therapeutic agents for ……”

23) Oldfield V, Plosker GL. Lopinavir /
ritonavir. Drugs. 2006; 66(9): 12751299.
24) CEBM. Oxford Centre for EvidenceBased Medicine: Levels of Evidence
(March 2009). 2009.
https://www.cebm.ox.ac.uk/resources/le
vels-of-evidence/oxford-centre-forevidence-based-medicine-levels-ofevidence-march-2009 (accessed
21/10/2020 2020).
25) Owa AB, Owa OT. Lopinavir/ritonavir
use in Covid-19 infection: is it
completely non-beneficial? Journal of
Microbiology,
Immunology
and
Infection. 2020.
26) Venkatasubbaiah M, Reddy PD,
Satyanarayana SV. Literature-based
review of the drugs used for the
treatment of COVID-19. Current
medicine research and practice. 2020;
10(3): 100-109.
27) Blaising J, Polyak SJ, Pécheur E-I.
Arbidol as a broad-spectrum antiviral: an
update. Antiviral research. 2014; 107:
84-94.
28) Pécheur E-I, Borisevich V, Halfmann P,
Morrey JD, Smee DF, Prichard M, et al.
The synthetic antiviral drug arbidol
inhibits globally prevalent pathogenic
viruses. Journal of virology. 2016; 90(6):
3086-3092.
29) Lian N, Xie H, Lin S, Huang J, Zhao J,
Lin Q. Umifenovir treatment is not
associated with improved outcomes in
patients with coronavirus disease 2019: a
retrospective
study.
Clinical
Microbiology and Infection. 2020.
30) Huang D, Yu H, Wang T, Yang H, Yao
R, Liang Z. Efficacy and safety of
umifenovir for coronavirus disease 2019
(COVID‐19): A systematic review and
meta‐analysis. Journal of Medical
Virology. 2020.
31) Deng L, Li C, Zeng Q, Liu X, Li X,
Zhang H, et al. Arbidol combined with
LPV/r versus LPV/r alone against
Corona Virus Disease 2019: A
retrospective cohort study. Journal of
Infection. 2020.

32) de Wit E, Feldmann F, Cronin J, Jordan
R, Okumura A, Thomas T, et al.
Prophylactic and therapeutic remdesivir
(GS-5734) treatment in the rhesus
macaque
model
of
MERS-CoV
infection. Proceedings of the National
Academy of Sciences. 2020; 117(12):
6771-6776.
33) Sheahan TP, Sims AC, Leist SR, Schäfer
A, Won J, Brown AJ, et al. Comparative
therapeutic efficacy of remdesivir and
combination lopinavir, ritonavir, and
interferon beta against MERS-CoV.
Nature communications. 2020; 11(1): 114.
34) Mulangu S, Dodd LE, Davey Jr RT,
Tshiani Mbaya O, Proschan M, Mukadi
D, et al. A randomized, controlled trial
of Ebola virus disease therapeutics. New
England Journal of Medicine. 2019;
381(24): 2293-2303.
35) Tchesnokov EP, Feng JY, Porter DP,
Götte M. Mechanism of inhibition of
Ebola virus RNA-dependent RNA
polymerase by remdesivir. Viruses.
2019; 11(4): 326.
36) Holshue ML, DeBolt C, Lindquist S,
Lofy KH, Wiesman J, Bruce H, et al.
First case of 2019 novel coronavirus in
the United States. New England Journal
of Medicine. 2020.
37) Grein J, Ohmagari N, Shin D, Diaz G,
Asperges E, Castagna A, et al.
Compassionate use of remdesivir for
patients with severe Covid-19. New
England Journal of Medicine. 2020;
382(24): 2327-2336.
38) Wang Y, Zhang D, Du G, Du R, Zhao J,
Jin Y, et al. Remdesivir in adults with
severe COVID-19: a randomised,
double-blind,
placebo-controlled,
multicentre trial. The Lancet. 2020.
39) Beigel JH, Tomashek KM, Dodd LE,
Mehta AK, Zingman BS, Kalil AC, et al.
Remdesivir for the treatment of Covid19—preliminary report. New England
Journal of Medicine. 2020.
40) Pardo J, Shukla AM, Chamarthi G,
Gupte A. The journey of remdesivir:

Palestinian Medical and Pharmaceutical Journal (PMPJ). 2022; 7(2): 117-138 ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ

Abdel Naser Zaid, et al.  ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ135

from Ebola to COVID-19. Drugs in
context. 2020; 9.
41) Sun D. Remdesivir for Treatment of
COVID-19: Combination of Pulmonary
and IV Administration May Offer
Aditional Benefit. The AAPS Journal.
2020; 22(4).
42) WHO. WHO recommends against the
use of remdesivir in COVID-19 patients.
20/11/2020
2020.
https://www.who.int/news-room/featurestories/detail/who-recommends-againstthe-use-of-remdesivir-in-covid-19patients (accessed 25/11/2020 at 19: 40
2020).
43) Cohen J, Kupferschmidt K. ‘A very,
very bad look’for remdesivir. American
Association for the Advancement of
Science; 2020.
44) Schrezenmeier
E,
Dörner
T.
Mechanisms
of
action
of
hydroxychloroquine and chloroquine:
implications for rheumatology. Nature
Reviews Rheumatology. 2020: 1-12.
45) Plantone D, Koudriavtseva T. Current
and future use of chloroquine and
hydroxychloroquine
in
infectious,
immune, neoplastic, and neurological
diseases: a mini-review. Clinical drug
investigation. 2018; 38(8): 653-671.
46) Pastick KA, Okafor EC, Wang F,
Lofgren SM, Skipper CP, Nicol MR, et
al., editors. Hydroxychloroquine and
chloroquine for treatment of SARSCoV-2 (COVID-19). Open Forum
Infectious Diseases; 2020: Oxford
University Press US.
47) Mahase E. Covid-19: six million doses
of hydroxychloroquine donated to US
despite lack of evidence. British Medical
Journal Publishing Group; 2020.
48) Geleris J, Sun Y, Platt J, Zucker J,
Baldwin M, Hripcsak G, et al.
Observational
study
of
hydroxychloroquine in hospitalized
patients with Covid-19. New England
Journal of Medicine. 2020.

49) Johnson DB, Kelley B. Dexamethasone.
StatPearls
[Internet]:
StatPearls
Publishing; 2019.
50) Allen K. Dexamethasone: An all purpose
agent?
Australasian
Anaesthesia.
2007(2007): 65.
51) Oray M, Abu Samra K, Ebrahimiadib N,
Meese H, Foster CS. Long-term side
effects of glucocorticoids. Expert
opinion on drug safety. 2016; 15(4):
457-465.
52) Group
RC.
Dexamethasone
in
hospitalized patients with Covid-19—
preliminary report. New England Journal
of Medicine. 2020.
53) Njoo F, Hack C, Oosting J, Luyendijk L,
Stilma J, Kijlstra A. C-reactive protein
and interleukin-6 are elevated in
onchocerciasis patients after ivermectin
treatment.
Journal
of
Infectious
Diseases. 1994; 170(3): 663-668.
54) Mastrangelo E, Pezzullo M, De
Burghgraeve T, Kaptein S, Pastorino B,
Dallmeier K, et al. Ivermectin is a potent
inhibitor of flavivirus replication
specifically targeting NS3 helicase
activity: new prospects for an old drug.
Journal of Antimicrobial Chemotherapy.
2012; 67(8): 1884-1894.
55) Fox LM. Ivermectin: uses and impact 20
years on. Current opinion in infectious
diseases. 2006; 19(6): 588-593.
56) Goa KL, McTavish D, Clissold SP.
Ivermectin. Drugs. 1991; 42(4): 640658.
57) Caly L, Druce JD, Catton MG, Jans DA,
Wagstaff KM. The FDA-approved drug
ivermectin inhibits the replication of
SARS-CoV-2 in vitro. Antiviral
research. 2020: 104787.
58) Momekov G, Momekova D. Ivermectin
as a potential COVID-19 treatment from
the pharmacokinetic point of view:
antiviral levels are not likely attainable
with
known
dosing
regimens.
Biotechnology &
Biotechnological
Equipment. 2020; 34(1): 469-474.
59) Klok F, Kruip M, Van der Meer N,
Arbous M, Gommers D, Kant K, et al.

 ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــPalestinian Medical and Pharmaceutical Journal (PMPJ). 2022; 7(2): 117-138

136 “ ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــA review of possible therapeutic agents for ……”

Incidence of thrombotic complications in
critically ill ICU patients with COVID19. Thrombosis research. 2020.

controversy. The Lancet.
397(10285): 1599-1601.

2021;

60) Kasinathan G, Sathar J. Haematological
manifestations,
mechanisms
of
thrombosis and anti-coagulation in
COVID-19 disease: A review. Annals of
Medicine and Surgery. 2020.

70) Bloch EM, Shoham S, Casadevall A,
Sachais BS, Shaz B, Winters JL, et al.
Deployment of convalescent plasma for
the prevention and treatment of COVID19. The Journal of clinical investigation.
2020; 130(6): 2757-2765.

61) Levi M, Thachil J, Iba T, Levy JH.
Coagulation
abnormalities
and
thrombosis in patients with COVID-19.
The Lancet Haematology. 2020; 7(6):
e438.

71) Rojas M, Rodríguez Y, Monsalve DM,
Acosta-Ampudia Y, Camacho B, Gallo
JE, et al. Convalescent plasma in Covid19: Possible mechanisms of action.
Autoimmunity Reviews. 2020: 102554.

62) Tang N, Li D, Wang X, Sun Z.
Abnormal coagulation parameters are
associated with poor prognosis in
patients
with
novel
coronavirus
pneumonia. Journal of thrombosis and
haemostasis. 2020; 18(4): 844-847.

72) Luke TC, Kilbane EM, Jackson JL,
Hoffman
SL.
Meta-analysis:
convalescent blood products for Spanish
influenza pneumonia: a future H5N1
treatment? Annals of internal medicine.
2006; 145(8): 599-609.

63) Tang N, Bai H, Chen X, Gong J, Li D,
Sun Z. Anticoagulant treatment is
associated with decreased mortality in
severe coronavirus disease 2019 patients
with
coagulopathy.
Journal
of
thrombosis and haemostasis. 2020;
18(5): 1094-1099.

73) Garraud O. Use of convalescent plasma
in Ebola virus infection. Transfusion and
apheresis science. 2017; 56(1): 31-34.

64) MedlinePlus.
Colchicine.
2020.
https://medlineplus.gov/druginfo/meds/a
682711.html (accessed oct 22 2020).
65) Johri R. Cuminum cyminum and Carum
carvi: An update. Pharmacognosy
reviews. 2011; 5(9): 63.
66) Montealegre-Gómez G, Garavito E,
Gómez-López A, Rojas-Villarraga A,
Parra-Medina R. Colchicine: a potential
therapeutic tool against COVID-19.
Experience of 5 patients. Reumatologia
Clinica. 2020.
67) Leung YY, Hui LLY, Kraus VB, editors.
Colchicine—Update on mechanisms of
action and therapeutic uses. Seminars in
arthritis and rheumatism; 2015: Elsevier.
68) Brennecke A, Villar L, Wang Z, Doyle
LM, Meek A, Reed M, et al. Is Inhaled
Furosemide A Potential Therapeutic For
COVID-19? The American Journal of
the Medical Sciences. 2020.
69) Gupta S, Leaf DE. Tocilizumab in
COVID-19:
some
clarity
amid

74) Hung IF, To KK, Lee C-K, Lee K-L,
Chan K, Yan W-W, et al. Convalescent
plasma treatment reduced mortality in
patients with severe pandemic influenza
A (H1N1) 2009 virus infection. Clinical
Infectious Diseases. 2011; 52(4): 447456.
75) Cheng Y, Wong R, Soo Y, Wong W,
Lee C, Ng M, et al. Use of convalescent
plasma therapy in SARS patients in
Hong Kong. European Journal of
Clinical Microbiology and Infectious
Diseases. 2005; 24(1): 44-46.
76) Ye M, Fu D, Ren Y, Wang F, Wang D,
Zhang F, et al. Treatment with
convalescent plasma for COVID‐19
patients in Wuhan, China. Journal of
Medical Virology. 2020.
77) Duan K, Liu B, Li C, Zhang H, Yu T,
Qu J, et al. Effectiveness of convalescent
plasma therapy in severe COVID-19
patients. Proceedings of the National
Academy of Sciences. 2020; 117(17):
9490-9496.
78) Shen C, Wang Z, Zhao F, Yang Y, Li J,
Yuan J, et al. Treatment of 5 critically ill
patients
with
COVID-19
with

Palestinian Medical and Pharmaceutical Journal (PMPJ). 2022; 7(2): 117-138 ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ

Abdel Naser Zaid, et al.  ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ137

convalescent plasma. Jama. 2020;
323(16): 1582-1589.
79) Joyner MJ, Wright RS, Fairweather D,
Senefeld JW, Bruno KA, Klassen SA, et
al. Early safety indicators of COVID-19
convalescent plasma in 5,000 patients.
The Journal of Clinical Investigation.
2020.
80) Liu KC-SC, Yang S-L, Roberts M,
Elford B, Phillipson J. Antimalarial
activity of Artemisia annua flavonoids
from whole plants and cell cultures.
Plant Cell Reports. 1992; 11(12): 637640.
81) Stebbings S, Beattie E, McNamara D,
Hunt S. A pilot randomized, placebocontrolled clinical trial to investigate the
efficacy and safety of an extract of
Artemisia annua administered over 12
weeks, for managing pain, stiffness, and
functional limitation associated with
osteoarthritis of the hip and knee.
Clinical rheumatology. 2016; 35(7):
1829-1836.
82) Slezáková
S,
Ruda-Kucerova
J.
Anticancer activity of artemisinin and its
derivatives. Anticancer Research. 2017;
37(11): 5995-6003.
83) Juteau F, Masotti V, Bessiere JM,
Dherbomez M, Viano J. Antibacterial
and antioxidant activities of Artemisia
annua essential oil. Fitoterapia. 2002;
73(6): 532-535.
84) Law S, Leung AW, Xu C. Is the
traditional Chinese herb “Artemisia
annua” possible to fight against COVID19? Integrative Medicine Research.
2020.

and treat coronavirus disease 2019
(COVID-19)? Medicine in Drug
Discovery. 2020; 5: 100028.
88) Razzaque M. COVID-19 Pandemic: Can
Maintaining Optimal Zinc Balance
Enhance Host Resistance? 2020.
89) WHO. Clinical management of COVID19: interim guidance. 2020 27\5\2020.
90) WHO. The push for a COVID-19
vaccine. 2020.
https://www.who.int/emergencies/diseas
es/novel-coronavirus-2019/covid-19vaccines (accessed November,24 2020).
91) WHO. DRAFT landscape of COVID-19
candidate vaccines –12 November 2020.
2020. https://www.who.int/docs/defaultsource/blue-print/novel-coronaviruslandscape-covid-19(7).pdf?sfvrsn=a4e55ae3_2&download=
true (accessed November,24 2020).
92) pfizer. PFIZER AND BIONTECH
CONCLUDE PHASE 3 STUDY OF
COVID-19 VACCINE CANDIDATE,
MEETING ALL PRIMARY
EFFICACY ENDPOINTS. November,
18 2020.
https://www.pfizer.com/news/pressrelease/press-release-detail/pfizer-andbiontech-conclude-phase-3-study-covid19-vaccine (accessed November, 24
2020).
93) Lowe D. Vaccine Efficacy Data! 9
November 2020.
https://blogs.sciencemag.org/pipeline/arc
hives/2020/11/09/vaccine-efficacy-data
(accessed Novwmber, 24 2020).

85) Cheong DH, Tan WD, Wong WF, Tran
T. Anti-malarial drug, artemisinin and its
derivatives for the treatment of
respiratory diseases. Pharmacological
Research. 2020: 104901.

94) Oxford UO. Oxford University
breakthrough on global COVID-19
vaccine. 23 November 2020.
https://www.ox.ac.uk/news/2020-11-23oxford-university-breakthrough-globalcovid-19-vaccine?hp (accessed
November, 24 2020).

86) McCartney DM, Byrne D. Optimisation
of vitamin D status for enhanced
Immuno-protection against Covid-19. Ir
Med J. 2020; 113(4): 58.

95) Cohen J. Vaccine wagers on coronavirus
surface protein pay off. American
Association for the Advancement of
Science; 2020.

87) Cheng RZ. Can early and high
intravenous dose of vitamin C prevent

96) Moderna. Moderna’s Work on a
COVID-19 Vaccine Candidate. 2020.

 ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــPalestinian Medical and Pharmaceutical Journal (PMPJ). 2022; 7(2): 117-138

138 “ ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــA review of possible therapeutic agents for ……”

https://www.modernatx.com/modernaswork-potential-vaccine-against-covid-19
(accessed November, 24 2020).
97) Organization WH. Status of COVID-19
vaccines
within
WHO
EUL/PQ
evaluation process. 2021. 2021.
98) Organization WH. Status of COVID-19
vaccines
within
WHO
EUL/PQ
evaluation process. Geneva, Switzerland.
2021.

99) Machhi J, Shahjin F, Das S, Patel M,
Abdelmoaty MM, Cohen JD, et al.
Nanocarrier vaccines for SARS-CoV-2.
Advanced Drug Delivery Reviews.
2021.
100)
Goyal M, Tewatia N, Vashisht H,
Jain R, Kumar S. Novel Corona Virus
(COVID-19); Global Efforts and
Effective Investigational Medicines: A
Review. Journal of Infection and Public
Health. 2021.

Palestinian Medical and Pharmaceutical Journal (PMPJ). 2022; 7(2): 117-138 ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ

